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ABSTRACT
Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as 
first-line treatment for transplantation-ineligible multiple myeloma (MM). This study 
investigated the efficacy of VMP for Korean patients with MM.
Overall, 177 MM patients received 9 cycles of VMP in this prospective, multicenter, 
observational study. The primary endpoint was 2-year progression-free survival (PFS).
Thirty-nine (22%) patients were aged ≥ 75 years and 83 (47.4%) patients had 
International Staging System stage III. A median of 5 cycles were delivered. Overall 
response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. With 
a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS and 
overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was not 
reached. PFS was significantly different depending on performance status (Eastern 
Cooperative Oncology Group < 2 vs. ≥ 2; p = 0.0002), β2-microglobulin level (< 5.5 vs. 
≥ 5.5 mg/L; p = 0.0481), and cumulative dose of bortezomib (< 35.1 vs. ≥ 35.1 mg/
m2; p < 0001). The common adverse events (AEs) were in line with the well-known 
toxicity profiles associated with VMP.
In conclusion, VMP is a feasible and effective front-line treatment for transplant-
ineligible older patients with MM in Korea. Continuing therapy with prompt adjustment 
of treatment according to AEs may be important to improve outcomes of elderly patients.
INTRODUCTION
Multiple myeloma (MM) is a progressive plasma 
cell neoplasm characterized by reduced resistance against 
infection, skeletal injuries (bone pain and fracture), renal 
failure, and anemia. The prognosis is mostly recurrent, 
with a median survival of approximately 3 to 4 years. 
Melphalan-prednisone (MP) has been the standard 
therapy for patients with newly diagnosed MM for over 
40 years, and is associated with a median survival of 29 to 
37 months [1, 2]. Studies have shown that treatment with 
MP resulted in partial response (PR) or greater responses 
in approximately half of the treated patients; however, 
complete response (CR) was relatively rare and median 
survival was approximately 3 years [3–6]. During the past 
decade, high-dose therapy with hematopoietic stem cell 
transplantation has become the preferred treatment for 
patients under the age of 65 years, but older patients and 
patients with clinically significant comorbidities usually 
do not tolerate this treatment.
With increasing incidence of MM among patients 
aged ≥ 70 years, it is becoming increasingly important to 
investigate treatment options in patients who are not eligible 
for autologous stem cell transplantation [7]. Several recent 
studies have proved the efficacy and safety of bortezomib 
in patients with recurrent or refractory MM [8] and the 
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Assessment of Proteasome inhibition for Extending 
Remissions (APEX) study has demonstrated the efficacy 
and safety of bortezomib as secondary therapy [9]. Based 
on the results of the Velcade as Initial Standard Therapy 
in Multiple Myeloma (VISTA) study, which showed a 
significant difference between bortezomib plus melphalan 
and prednisone (VMP) therapy compared to MP therapy in 
terms of CR, time to progression (TTP), and overall survival 
(OS), VMP is now recognized as a standard therapy for MM 
patients aged ≥ 65 years [10]. A retrospective analysis of 
the VISTA study suggested that higher cumulative doses 
of bortezomib, reflecting prolonged treatment duration and/
or greater dose intensity, could lead to improved OS [11].
The incidence of MM in Korea has increased 
steadily, and it is the second most common hematologic 
malignancy in Korea since 2012 [12]. Currently, VMP 
is the most commonly used regimen for treating patients 
who are ineligible for transplantation. However, data on 
the efficacy and safety of VMP therapy in Asian patients 
with MM are limited.
Thus, we performed a prospective, multicenter, 
observational study to investigate the clinical effectiveness 
and safety of VMP treatment for Korean patients with MM.
RESULTS
Patient characteristics
In total, 179 patients were enrolled into this 
observational study at 38 centers in Korea from May 22, 
2011 to May 29, 2014, of whom 177, who received at least 
1 dose of the study drug, were included in the analyses. 
The study population comprised 102 (57.6%) men and 75 
(42.4%) women, with a median age of 71 years; 39 (22%) 
patients were aged ≥ 75 years. The most common subtype 
of MM at the time of diagnosis was immunoglobulin (Ig) G 
type of MM in 108 (61.0%) patients, followed by IgA type 
in 43 (24.3%) patients, and IgM type in 2 (1.1%) patients. 
Overall, 20 (11.3%) patients had light chain disease and 4 
(2.3%) had the non-secretory type of MM. According to 
the International Staging System (ISS), 22 (12.6%) patients 
were in stage I, 70 (40.0%) were in stage II, and 83 (47.4%) 
were in stage III (Table 1). In total, 83 (47.4%) patients 
had a serum β2-microglobulin level of > 5.5 mg/L and 129 
(73.7%) had glomerular filtration rate < 60 mL/min.
Cytogenetic test results were collected in 145 patients 
at the time of diagnosis of MM. The high-risk cytogenetics 
group included 24 (13.6%) patients, classified on the basis 
of karyotypic deletion 13 or hypodiploidy or the presence 
of deletion 17p, translocation (4;14), or translocation 
(14;16) on interphase florescence in situ hybridization.
Treatment data
At 100% dose intensity, the maximum planned 
cumulative dose of bortezomib was 67.6 mg/m2, including 
41.6 mg/m2 during cycles 1–4 and 26 mg/m2 during 
cycles 5–9. The maximum planned cumulative dose of 
melphalan and prednisone was 324 mg/m2 and 2160 mg/
m2, respectively. The median number of cycles delivered 
was 5 (range, 1–9), and the median cumulative dose 
of bortezomib was 35.1 mg/m2. The dose intensity of 
bortezomib, which is the median cumulative dose during 
the initial 4 cycles, was 25.6 mg/m2 (median relative dose 
intensity (RDI), 83.08%), while the median cumulative 
dose intensity from cycle 5 onwards was 20.0 mg/m2 
(median RDI, 87.35%). The median cumulative dose of 
melphalan and prednisone was 144 mg/m2 and 1200 mg/
m2, respectively. Of 177 patients, 58 completed 9 cycles 
of VMP therapy and 52 completed the 2-year follow-up. 
Among 119 patients who terminated the therapy before 
the end of the 9 cycles, the most common reason for 
termination of therapy was adverse events (AEs) in 26 
patients, death in 20 patients, disease progression in 19 
patients, and initiation of the next therapy in 17 patients. 
For 39 patients who were aged ≥ 75 years, the median 
number of treatment cycles was 3, and the median 
cumulative dose of bortezomib was 28.8 mg/m2.
Treatment response
Response was observed in 129 (72.9%) out of 177 
patients (95% confidence interval [CI], 65.7%–79.3%). 
Details regarding responses to treatment are shown in 
Table 2. The overall response rate (ORR; stringent CR 
[sCR], CR, very good partial response [VGPR], and PR) 
was 72.9%, and the CR rate (sCR and CR) was 20.3%. 
For 129 patients who responded to therapy, the median 
time to first response was 1.6 months, mostly in cycles 1 
and 2 in 84 (65.1%) and 29 (22.5%) patients, respectively. 
The median time to best response was 3.4 months, mostly 
in cycles 1, 2, 3, and 4, each in 38 (29.5%) patients, 29 
(22.5%) patients, 25 (19.4%) patients, and 15 (11.6%) 
patients, respectively (Figure 1). The median duration of 
response was 17.1 months for the overall population, and 
20.6 months for patients with CR.
Survival data
The median follow-up duration for 177 patients 
was 11.9 months. The projected 2-year progression-free 
survival (PFS) rate was 29.2% (95% CI, 20.4%–38.5%), 
and the median PFS was 17 months (95% CI, 13.6–19.1 
months). The projected 2-year OS rate was 80.0% (95% 
CI, 71.9%–85.9%) and median OS was not reached 
(Figure 2). During the safety follow-up period, 26 (14.7%) 
patients died.
In univariate analysis for factors affecting 2-year PFS 
rate, Eastern Cooperative Oncology Group performance 
status (ECOG-PS) and cumulative dose of bortezomib 
were significantly associated with PFS, while serum β2-
microglobulin concentration tended to be associated with 
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Table 1: Patient demographics and baseline characteristics
Category
N = 177
n (%)
Sex
 Male 102 (57.6)
 Female 75 (42.4)
Age (years)
 Median (range) 71 (48–86)
 ≥ 75 years 39 (22.0)
Type of myeloma
 IgG 108 (61.0)
 IgA 43 (24.3)
 IgM 2 (1.1)
 Light chain 20 (11.3)
 Non-secretory 4 (2.3)
Stage - Durie–Salmon Staging System
 I 13 (7.3)
 II 51 (28.8)
 III 113 (63.8)
Stage - International Staging System
 I 22 (12.6)
 II 70 (40.0)
 III 83 (47.4)
Skeletal lesions
 0 33 (18.6)
 1–2 44 (24.9)
 ≥ 3 80 (45.2)
 Unknown 20 (11.3)
ECOG-PS
 0 11 (6.2)
 1 104 (58.8)
 2 42 (23.7)
 3 19 (10.7)
 4 1 (0.6)
Serum β2-microglobulin (mg/L)
 Median (range) 5.3 (0–35.3)
 < 2.5 17 (9.7)
 2.5–5.5 75 (42.9)
 > 5.5 83 (47.4)
Albumin (g/dL)
 Median (range) 3.3 (1.0–5.1)
 < 3.5 107 (61.1)
 ≥ 3.5 68 (38.9)
(Continued)
Oncotarget37609www.impactjournals.com/oncotarget
PFS (Table 3). Multivariate analysis showed that ECOG-
PS < 2 (vs. ≥ 2), β2-microglobulin < 5.5 mg/L (vs. ≥ 5.5 
mg/L), and cumulative dose of bortezomib ≥ 35.1 mg/m2 
(vs. < 35.1 mg/m2) were independent predictors for longer 
PFS (Table 4). β2-microglobulin < 5.5 mg/L, albumin ≥ 
3.5 g/L, and cumulative dose of bortezomib ≥ 35.1 mg/
m2were independent prognostic factors for OS (Table 4). 
Patient age ≥ 75 years, impaired renal function, advanced 
ISS stage, and high-risk cytogenetic abnormalities did not 
significantly affect the PFS and OS. Figure 3 shows the 
PFS and OS according to cumulative bortezomib dose (≥ 
35.1 vs. < 35.1 mg/m2).
Adverse events
Overall, 174 (98.3%) patients reported 2,072 AEs, 
and 154 (87.0%) patients reported 1,095 adverse drug 
reactions (ADRs). Serious adverse events (SAEs) were 
reported by 121 (68.4%) patients (277 events). Of these, 
29 AEs in 26 (14.7%) patients resulted in death. The 
most common AE was diarrhea in 71 (40.1%) patients, 
followed by asthenia in 66 (37.3%) patients, peripheral 
neuropathy in 60 (33.9%) patients, decreased appetite in 
53 (29.9%) patients, and nausea in 50 (28.3%) patients. 
Major hematologic AEs were cytopenias; grade 3 or 4 
neutropenia (14.7%), thrombocytopenia (10.7%), and 
anemia (3.4%) were frequently observed (Table 5).
There were 380 dose reductions cases in 70 patients 
(39.5%) during 1–9 cycles; the main cause was AEs in 
65 patients (92.8%). There were 4 deaths considered 
treatment-related: 4 from pneumonia, including 1 from 
aspiration pneumonia.
DISCUSSION
Although the superiority of VMP over MP therapy in 
transplant-ineligible MM patients was demonstrated in the 
large randomized phase III VISTA study [10], prospective 
studies supporting the efficacy of VMP therapy in Asian 
countries are limited. This prospective multicenter study 
evaluated the efficacy and safety of VMP therapy for 
Korean patients with MM. Considering the potential gap 
between efficacy and effectiveness of new treatments 
in elderly myeloma patients, this population-based 
observational study is meaningful as it reflects outcomes 
in clinical practice.
Category
N = 177
n (%)
Creatinine clearance (mL/min)
 Median (range) 43.6 (5.8–106.6)
 < 60 129 (73.7)
 ≥ 60 46 (26.3)
Comorbidity
 No 40 (22.6)
 Yesb 137 (77.4)
 Allergy 1 (0.6)
 Renal impairment 31 (17.5)
 Hepatic impairment 5 (2.8)
 Others 129 (72.9)
Cytogenetics abnormality category
 Standard risk 121 (68.4)
 High riska 24 (13.6)
 Deletion 13 by karyotypeb 17 (9.6)
 Deletion 17p by FISHb 7 (4.0)
 t(4:14) by FISHb 6 (3.4)
 t(14:16) by FISHb 4 (2.3)
 Hypodiploidy by karyotypeb 2 (1.1)
 Test not done 32 (18.1)
a High risk cytogenetics: deletion 13 by karyotype, deletion 17p by FISH/karyotype, t(4;14), t(14;16), and hypodiploidy.
b Multiple counting.
FISH, fluorescence in situ hybridization.
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Figure 1: Time to first response A. and time to best response B.
Table 2: Best response to treatment
Category N = 177 %
sCR 3 1.7
CR 33 18.6
VGPR 47 26.6
PR 46 26.0
SD 19 10.7
PD 2 1.1
NE 27 15.3
ORR (≥ PR) (95% CI) 129 72.9 (65.7–79.3)
CRR (sCR + CR) (95% CI) 36 20.3 (14.7–27.0)
CRR, complete response rate; NE, not evaluable; PD, progressive disease; SD, stable disease.
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The results were comparable to the overall efficacy 
results of recently published VMP trials [10, 13–15]. 
Table 6 summarizes the baseline characteristics and VMP 
treatment results from recently published studies [11, 
14, 15]. The ORR in our study was similar to that from 
previous VMP studies. However, the PFS of patients in our 
study was shorter than that of patients in the VISTA study. 
This discrepancy may be because patients with advanced 
disease and poor performance were more common in 
our population. The US community-based phase IIIB 
UPFRONT study compared three frontline bortezomib-
based regimens in transplant-ineligible patients with 
MM. The median PFS in the UPFRONT study was 17.3 
months, similar to our results [14]. This shorter PFS may 
Figure 2: Kaplan–Meier curves for progression-free survival A. and overall survival B.
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Table 3: Univariate analysis for progression-free survival and overall survival
Group n 2-year PFS p valuea 2-year OS p valuea
Age, years 0.415 0.821
 < 75 138 28.6 80.5
 ≥ 75 39 31.2 78.6
Sex 0.520 0.305
 Male 102 28.1 76.4
 Female 75 31.2 85.6
ECOG-PS < 0.0001 0.005
 0, 1 115 37.6 84.9
 ≥ 2 62 13.4 70.8
β2-microglobulin,  
mg/dLb
0.065 0.029
 < 2.5 17 80.1 87.4
 2.5–5.5 75 23.8 88.8
 > 5.5 83 25.9 70.9
Albumin, g/dLb 0.344 0.063
 < 3.5 107 31.4 75.4
 ≥ 3.5 68 25.6 86.2
ISS stageb 0.220 0.025
 I 22 0.0 88.9
 II 70 35.2 88.2
 III 83 25.9 70.9
Creatinine clearance, 
mL/minb
0.618 0.459
 ≥ 60 129 28.6 79.1
 < 60 46 31.7 81.9
Cytogenetics riskb 0.312 0.298
 Standard 121 25.9 77.5
 High 24 43.3 90.6
Cumulative dose of 
bortezomib < 0.0001 < 0.0001
 < 35.1 mg/m2 88 14.3 54.9
 ≥ 35.1 mg/m2 89 38.0 94.7
a Log-rank test p value.
b Microglobulin values missing in 2 patients, albumin values missing in 2 patients, ISS stage values missing in 2 patients, 
creatinine clearance values missing in 2 patients, and cytogenetics risk assessment missing in 24 patients.
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Figure 3: Progression-free survival A. and overall survival B. by cumulative dose of bortezomib (≥35.1 vs. <35.1 mg/m2).
Table 4: Multivariate Cox proportional analysis for progression-free survival and overall survival
Factors
PFS OS
HR
95% HR CI
p valuea HR
95% HR CI
p valuea
(Lower, Upper) (Lower, Upper)
ECOG-PS, ≥ 2 2.236 (1.454, 3.438) 0.0002 - - -
β2-microglobulin, ≥ 5.5 
mg/dL
1.549 (1.004, 2.390) 0.0481 3.624 (1.546, 8.492) 0.003
Cumulative dose of 
bortezomib ≥ 35.1 mg/m2
0.287 (0.181, 0.453) < 0.0001 0.048 (0.015, 0.153) < 0.0001
Albumin, ≥ 3.5 g/dL - - - 0.344 (0.142, 0.835) 0.0183
HR, hazard ratio.
a Cox proportional hazards regression model.
Model Fit and Testing Global Ho- Likelihood ratio test: p = < 0.0001.
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also reflect the modification of treatment or differences 
between patients in the community setting. In our study, 
patients received a median of 5 cycles of VMP treatment 
compared to 8 cycles in the VISTA trial. The median time 
to CR was similar to that in the VISTA trial. The CR rate 
may be lower because the median number of treatment 
cycles was lower than in other studies. Considering 
that prolonged treatment might improve the quality of 
response, early discontinuation of treatment may have 
negatively affected the outcomes of this study.
In a phase I/II study of VMP in Japanese patients, 
VMP with 1.3 mg/m2 of bortezomib showed an ORR of 
69.8% and survival outcome was not reported. Similar 
to our study, the median number of treatment cycles 
was 4.5 [15]. The incidence of grade 4 neutropenia and 
thrombocytopenia was 30% and 22%, respectively. 
Peripheral neuropathy was the most common cause 
of discontinuation of study treatment. Owing to the 
limitation of an observational study design, the frequency 
and severity of AEs in our study and the UPFRONT 
study seem to be mostly underestimated. However, the 
incidences of herpes zoster infection and pneumonia 
were highest in our study. The treatment may have been 
terminated early due to AEs in both the Japanese and 
Korean studies.
Post-hoc landmark analysis of the VISTA study 
suggested that a higher cumulative dose of bortezomib 
and continued VMP treatment following attainment of 
CR might result in improved OS [11]. In our subgroup 
analysis, cumulative dose of bortezomib was also 
Table 5: Adverse events
Adverse Events
Total Grade 3 Grade 4
n (%)
Any event 174 (98.3) 110 (62.2) 32 (18.1)
Gastrointestinal disorders
 Diarrhea 71 (40.1) 25 (14.1) 1 (0.6)
 Nausea 50 (28.3) 2 (1.1) 0 (0.0)
 Constipation 48 (27.1) 2 (1.1) 0 (0.0)
 Vomiting 31 (17.5) 2 (1.1) 0 (0.0)
Nervous system disorders
 Neuropathy peripheral 60 (33.9) 10 (5.7) 0 (0.0)
 Dizziness 30 (17.0) 2 (1.1) 0 (0.0)
Infections and infestations
 Pneumonia 43 (24.3) 16 (9.0) 3 (1.7)
 Herpes zoster 27 (15.3) 9 (5.1) 0 (0.0)
Blood and lymphatic system disorders
 Neutropenia 32 (18.1) 19 (10.7) 7 (4.0)
 Thrombocytopenia 31 (17.5) 14 (7.9) 5 (2.8)
 Anemia 18 (10.2) 6 (3.4) 0 (0.0)
 Leukopenia 4 (2.3) 0 (0.0) 1 (0.6)
Other conditions
 Asthenia 66 (37.3) 18 (10.2) 0 (0.0)
 Decreased appetite 53 (29.9) 6 (3.4) 0 (0.0)
 Pyrexia 43 (24.3) 0 (0.0) 1 (0.6)
 Back pain 35 (19.8) 7 (4.0) 0 (0.0)
 Fatigue 29 (16.4) 5 (2.8) 0 (0.0)
 Dyspnea 28 (15.8) 4 (2.3) 1 (0.6)
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an important factor for favorable outcome. Experts 
have recommended prompt dose adjustment of novel 
myeloma drugs according to the patient’s condition 
because continuous treatment until disease progression or 
intolerability increases the depth of response and extended 
survival [16]. Early adjustment of treatment according to 
frailty status and AEs is essential to continue treatment 
and improve outcome of patients treated with VMP 
regimen. Subcutaneous injection of bortezomib showed 
improvements in tolerability of treatment [17]. A less 
intensive VMP regimen with weekly bortezomib schedule 
was investigated to prolong treatment duration, and similar 
outcomes were achieved [16, 18]. Dose reductions based 
on geriatric assessment may help reduce treatment toxicity 
and avoid early discontinuation of treatment [19].
Intriguingly, none of the potential prognostic factors 
such as advanced age, renal impairment, and high-risk 
cytogenetic profiles were found to predict survival with 
VMP therapy. This is consistent with the results of previous 
studies with bortezomib, suggesting that it may overcome 
some of the poor prognostic impact of these factors [9–11, 
13]. Although VMP therapy is a well-established standard 
treatment for patients with MM who are ineligible for high-
dose therapy, it is not clear whether very elderly patients 
should be treated with VMP, considering the toxicities. In 
our study, there was no difference in PFS for patients who 
were aged ≥ 75 years. Based on this, it is suggested that 
VMP may be an effective treatment option even in very 
elderly patients. Few studies have been dedicated to patients 
over the age of 75 years, and currently no studies have been 
designed based on frailty. Prospective studies are warranted 
to improve outcomes of these populations. Recently, 
alkylator-free continuous lenalidomide-dexamethasone (Rd) 
given until disease progression showed superior PFS and OS 
to melphalan-prednisone-thalidomide (MPT) in transplant-
ineligible patients with myeloma [20]. According to the 
updated results, continuous Rd also demonstrated benefits 
over MPT for patients older than 75 years [21]. Currently, 
both fixed duration of alklyator-combining therapy and 
continuous alklyator-free regimen are considered as standard 
treatment for transplant-ineligible MM patients. Further 
prospective studies may clarify strategies that are more 
effective for elderly patients.
This is one of the largest multicenter studies to 
evaluate prospectively the efficacy of VMP therapy in 
transplant-ineligible MM patients in Asian countries. VMP 
therapy showed similar results as in previous studies in 
Korean MM patients. We confirmed that VMP is a feasible 
Table 6: Comparison of results of VMP treatment group among recent studies
VISTA study UPFRONT study Japanese study Korean study
No. of patients 344 167 87 177
Median age, years 71 (57-90) 72 (68-77) 71 (48-84) 71 (48-86)
≥ 75 years (%) 31 37 27.6 22
ISS stage III (%) 35 36 27.6 47.4
ORR (CR/VGPR/PR) (%)a 74 70 69.8 72.9
CR (%) 33 32c 19.8 20.3
Time to best response, median (months)a 4.2 NA NA 3.4
Duration of response, median (months) 19.9 19.8 NA 17.1
Number of cycles, median (range) 8 7 4.5 5
PFS, median (months) 24b 17.3 NA 17.0
OS, median (months) 56.4 53.1 NA NA
Neutropenia, any grade (%) 49 23 97 18.1
Thrombocytopenia, any grade (%) 52 18 98 17.5
Peripheral neuropathy, any grade (%) 44 47 67 33.9
Herpes zoster, any grade (%) 13 6 7 15.3
Pneumonia, any grade (%) 16 6 11d 24.3
NA, not available.
a Response by International Uniform Response Criteria.
b Time to progression.
c CR + near CR.
d Incidence of lung injury associated with bortezomib.
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and effective front-line treatment for transplant-ineligible 
older patients with MM in Korea. Continuing therapy with 
prompt adjustment of treatment according to AEs may be 
important to improve outcomes of elderly patients.
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors' 
institutional review board.
Patients
The study population included patients with 
untreated, symptomatic, measurable MM who were 
not eligible for autologous stem cell transplantation. 
Symptomatic MM was defined as the presence of 
intramedullary monoclonal plasma cells ≥ 10% or 
histologically confirmed plasmacytoma, or presence of 
monoclonal protein in the serum or urine, or myeloma-
related organ impairment. Measurable disease was defined 
as the presence of quantifiable M protein in serum or 
urine for secretory MM or confirmed abnormal free light 
chain ratio for non-secretory MM. The exclusion criteria 
were asymptomatic MM or monoclonal gammopathy of 
undetermined significance, previous treatment for MM, 
severe peripheral neuropathy (grade ≥ 2 according to 
National Cancer Institute Common Toxicity Criteria for 
Adverse Events [NCI-CTCAE] version 4.0), pregnancy 
or breastfeeding, mental illness, or other serious medical 
conditions.
Study design and treatments
The patients received VMP treatment guided by 
approved label which comprised nine 6-week cycles of 
melphalan (at a dose of 9 mg/m2) and prednisone (at a 
dose of 60 mg/m2) on days 1 to 4 in combination with 
bortezomib (at a dose of 1.3 mg/m2) on days 1, 4, 8, 11, 
22, 25, 29, and 32 during cycles 1 to 4, and on days 1, 8, 
22, and 29 during cycles 5 to 9.
With one cycle consisting of 6 weeks (42 days) from 
the day when VMP was started, the planned treatment 
duration was up to 9 cycles, and the follow-up period was 
2 years from the day when VMP was started. Considering 
the observational nature of the study, doses, administration 
interval, and total treatment cycles could be modified 
based on the investigator’s discretion. After completion 
of treatment or withdrawal of study drug (due to SAEs 
or disease progression), patients were followed up for 2 
years from the start of VMP treatment. Follow-up was 
discontinued and considered completed when the next 
therapy was initiated because of disease progression or 
death during the 9 cycles of VMP therapy or the follow-
up period.
Study endpoints and assessments
The primary endpoint was the 2-year PFS rate. The 
secondary endpoints were ORR, CR rate, time to response, 
and OS. Response and progression were assessed by 
investigators according to the International Myeloma 
Working Group uniform criteria [22].
Efficacy and safety were evaluated for all subjects 
who had received at least one dose of bortezomib. All 
AEs were reported from the start date of bortezomib 
administration to 30 days after the last administration 
date. The severity of the AEs was evaluated according 
to the NCI-CTCAE version 4.0 (http://ctep.cancer.gov/
protocolDevelopment/electronic_applications/ctc.htm).
PFS was defined as the length of time from the day 
of bortezomib first administration to disease progression, 
relapse from CR, or death, whichever occurred first, in 2 
years. OS was defined as the time between bortezomib 
first administration and death. Death, regardless of the 
cause, was considered as an event. Duration of response 
was defined as the time from the date of first evidence 
of achievement of at least a minor response until date of 
disease progression, relapse, or death from any cause.
Statistical analysis
Demographic and baseline data as well as 
effectiveness data were summarized using descriptive 
statistics. Descriptive statistics were presented as 
continuous variables, which included the mean, standard 
deviation, median, and range (minimum and maximum), 
and as categorical variables, which included frequencies 
and their respective percentages. Time-to-event outcome, 
including OS, PFS, and duration of response, was analyzed 
using Kaplan–Meier method.
Differences between groups were compared using 
the chi-square test or Fisher’s exact test for categorical 
variables and t-test for continuous variables. Survival 
curves between subgroups were compared using the log-
rank test for univariate analysis, and multivariate analysis 
was performed using Cox’s proportional hazard model for 
survival. Factors with p values < 0.1 in univariate analyses 
were examined using multivariate regression models. 
For the multivariate analyses, a stepwise approach was 
used. All statistical tests were 2-sided, with significance 
defined as p < 0.05. Analyses were performed using SAS 
version 9.2.
Abbreviations
AE: adverse event; CI: confidence interval; CR: 
complete response; ECOG: Eastern Cooperative Oncology 
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Group; Ig: immunoglobulin; ISS: International Staging 
System; MM: multiple myeloma; MP: melphalan-
prednisone; PFS: progression-free survival; PR: partial 
response; ORR: overall response rate; OS: overall 
survival; RDI: relative dose intensity; SAE: serious 
adverse event; sCR: stringent complete response; VGPR: 
very good partial response; VMP: bortezomib-melphalan-
prednisone.
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